1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CAVA Group reported fiscal second-quarter 2025 results for the period ended July 13, 2025, with CAVA Revenue up 20.3% to $278.2 million on 16 net new restaurant openings and same restaurant sales growth of 2.1%. Net income fell to $18.4 million from $19.7 million a year earlier, while Adjusted EBITDA rose 22.6% to $42.1 million, and the company cut its full-year same restaurant sales growth outlook to 4.0% to 6.0% from 6.0% to 8.0%.
CAVA Revenue grew 20.3% to $278.2 million versus $231.4 million in the prior-year quarter; total revenue was $280.6 million.
Net income was $18.4 million, down from $19.7 million; diluted EPS was $0.16 versus $0.17 a year earlier.
Adjusted EBITDA rose to $42.1 million from $34.3 million; CAVA Restaurant-Level Profit Margin was 26.3% versus 26.5%.
Updated fiscal 2025 guidance: same restaurant sales growth cut to 4.0% to 6.0%; net new openings raised to 68 to 70; Adjusted EBITDA unchanged at $152.0 million to $159.0 million.
Madison Square Garden Sports Corp. (MSGS) reported fiscal 2025 revenues of $1.04 billion, up 1%, but operating income fell to $14.8 million and the company recorded a net loss of $22.4 million for the year. In the fourth quarter, revenue fell 10% to $204.0 million and the company posted an operating loss, mainly due to higher direct operating expenses, which matters to shareholders because profit fell sharply even as annual sales edged up.
Fiscal 2025 revenues were $1,039.2 million, up $12.1 million, or 1%, from the prior year
Fiscal 2025 operating income was $14.8 million, down $131.2 million; net loss was $22.4 million, or $0.93 per diluted share
Fourth-quarter revenues were $204.0 million, down $23.3 million, or 10%; operating loss was $22.6 million versus operating income of $52.3 million a year earlier
Fourth-quarter direct operating expenses rose $47.1 million, or 44%, including $42.8 million of higher net provisions for certain team personnel transactions
Liquidia reported second quarter 2025 total revenue of $8.8 million, up from $3.7 million a year earlier, as YUTREPIA began commercial sales after FDA approval on May 23, 2025. The net loss widened to $41.6 million, or $0.49 per share, from $28.7 million, or $0.38 per share, as selling, general and administrative expenses rose to $38.8 million. Cash and cash equivalents were $173.4 million at June 30, 2025, and the filing includes no financial guidance.
Total revenue was $8.8 million versus $3.7 million a year earlier, including $6.5 million in YUTREPIA product sales.
Net loss was $41.6 million, or $0.49 per share, compared with $28.7 million, or $0.38 per share.
SG&A expenses were $38.8 million versus $19.9 million, including a $5.8 million rise in legal fees tied to YUTREPIA litigation.
As of August 8, specialty pharmacies reported more than 900 unique patient prescriptions and more than 550 patient starts.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.